SillaJen
215600.KQ
1.61 USD
-0.01
-0.62%
s
Overview
Last close
1.61 usd
Market cap
219.45M usd
52 week high
3.48 usd
52 week low
1.28 usd
Target price
N/A usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
27.3336
Price/Book Value
2.9449
Enterprise Value
170.78M usd
EV/Revenue
21.2217
EV/EBITDA
-23.7838
Key financials
Revenue TTM
8.05M usd
Gross Profit TTM
5.58M usd
EBITDA TTM
-18.82M usd
Earnings per Share
-0.13 usd
Dividend
N/A usd
Total assets
69.36M usd
Net debt
N/A usd
About
SillaJen, Inc., together with its subsidiaries, engages in developing technologies and products using genetic engineering in South Korea. Its clinical pipeline includes Pexa-Vec, which is in phase 2 clinical trial to treat renal cell carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. The company also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. In addition, it operates in biotechnology research industry. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
- Symbol215600.KQ
- ExchangeKQ
- IsinKR7215600008
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CEODr. Eun-Sang Moon D.D.S., DDS, M.D.
- HeadquarterSeoul
- Web sitehttps://www.sillajen.com
